SCTX,JSPR Stock Price and Quote

Peers: CRSP PRME BEAM NTLA EDIT DTIL SLN ARWR MGX IONS

| Held by: ARKG VTI IWM VXF VTWO IWO IWN IWC BUSM VTWG

Index	RUT
Market Cap	296.47M
Enterprise Value	417.09M
Income	-
Sales	-
Book/sh	-8.71
Cash/sh	2.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.89
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.57
Current Ratio	0.57
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.85
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02 AMC
EPS/Sales Surpr.	27.58% -38.16%

Insider Own	36.14%
Insider Trans	224.01%
Inst Own	25.93%
Inst Trans	20.61%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.83%
SMA50	-37.68%
SMA200	-35.70%
Trades

Shs Outstand	18.93M
Shs Float	12.09M
Short Float	20.40%
Short Ratio	6.71
Short Interest	2.47M
52W High	39.60 -60.45%
52W Low	13.50 16.00%
Volatility	11.77% 14.58%
ATR (14)	2.85
RSI (14)	34.25
Beta	-
Rel Volume	2.74
Avg Volume	367.56K
Volume	254,390

Perf Week	-22.01%
Perf Month	-27.53%
Perf Quarter	-17.45%
Perf Half Y	-
Perf YTD	-37.36%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	57.00
Prev Close	17.96
Price	15.66
Change %	-12.81%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-26	Initiated	H.C. Wainwright	Buy	$60
Aug-18-26	Initiated	Wells Fargo	Overweight	$60
Aug-18-26	Initiated	Leerink Partners	Outperform	$37
Aug-18-26	Initiated	Guggenheim	Buy	$50

Sep-28-26 03:11PM	Cathie Wood Makes $64 Million Bet on Two Stocks (GuruFocus.com)
Sep-22-26 07:10AM	Beyond Meta, Cathie Woods ARKG Loads Up On These 4 Biotech Names (Stocktwits)
Sep-02-26 04:05PM	Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.55%
Sep-01-26 08:00AM	Scribe Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.04%
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) +7.38%
09:37AM	Loading…
Aug-18-26 09:37AM	Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls (The Fly) +27.94%
Jul-27-26 04:08PM	Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com) -12.38%
04:05PM	Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement (GlobeNewswire)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AH Bio Fund II, L.P.	10% Owner	Jul 27 '26	Buy	15.00	333,333	4,999,995	2,385,075	Jul 29 07:09 PM
GORDON CARL L	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:50 PM
ORBIMED ADVISORS LLC	Director	Jul 27 '26	Buy	15.00	1,000,000	15,000,000	1,348,825	Jul 29 06:47 PM
Aghazadeh Behzad	Director	Jul 24 '26	Buy	15.15	2,383,333	36,115,495	3,080,983	Jul 28 09:30 PM
Aghazadeh Behzad	Director	Jul 28 '26	Buy	18.25	7,905	144,266	3,088,888	Jul 28 09:30 PM
Lucas Svetlana	Chief Business Officer	Jul 23 '26	Buy	15.00	3,000	45,000	3,000	Jul 27 09:42 PM
Parrot David	Chief Financial Officer	Jul 23 '26	Buy	15.00	2,666	39,990	1,333	Jul 27 09:20 PM

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

Co-FounderDr. Benjamin L. Oakes Ph.D.

CFO & TreasurerMr. David L. Parrot M.B.A.

Chief Operating OfficerDr. Svetlana Lucas Ph.D.

Co-Founder & Scientific AdvisorDr. Jennifer A. Doudna Ph.D.

Co-Founder & VP of External InnovationMr. Brett T. Staahl Ph.D.

JSPR Jasper Therapeutics Inc daily Stock Chart

Peers: COGT EVMN CNTB UPB ATTO ORKA ANAB ALDX ZURA JBIO

| Held by: VTI VXF

Index	-
Market Cap	16.20M
Enterprise Value	8.74M
Income	-31.77M
Sales	0.00M
Book/sh	0.05
Cash/sh	0.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	22
IPO	Jan 10, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	9.68
P/C	2.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.47
Current Ratio	1.47
Debt/Eq	0.19
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.58
EPS next Y	-0.52
EPS next Q	-0.06
EPS this Y	88.35%
EPS next Y	-12.32%
EPS next 5Y	48.38%
EPS past 3/5Y	27.39% 48.97%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.74%
Sales Y/Y TTM	-
EPS Q/Q	94.48%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	62.66% -

Insider Own	10.38%
Insider Trans	0.00%
Inst Own	27.64%
Inst Trans	-
ROA	-109.05%
ROE	-255.05%
ROIC	-2248.48%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.44%
SMA50	-22.14%
SMA200	-44.51%
Trades

Shs Outstand	33.27M
Shs Float	29.82M
Short Float	20.85%
Short Ratio	12.63
Short Interest	6.22M
52W High	2.52 -80.67%
52W Low	0.32 54.55%
Volatility	9.18% 9.73%
ATR (14)	0.05
RSI (14)	37.66
Beta	3.31
Rel Volume	0.68
Avg Volume	492.51K
Volume	84,736

Perf Week	1.48%
Perf Month	-16.81%
Perf Quarter	-29.86%
Perf Half Y	-41.91%
Perf YTD	-73.39%
Perf Year	-79.10%
Perf 3Y	-93.42%
Perf 5Y	-99.58%
Perf 10Y	-
Recom	1.00
Target Price	9.00
Prev Close	0.50
Price	0.49
Change %	-1.74%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-26	Resumed	William Blair	Outperform
Aug-12-26	Initiated	Piper Sandler	Overweight	$2
May-15-26	Downgrade	TD Cowen	Buy → Hold
Mar-23-26	Resumed	UBS	Neutral	$1.50
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$17
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$5
Jul-08-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$4
Jul-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-07-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Initiated	UBS	Buy	$38
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$63
Sep-09-24	Initiated	JMP Securities	Mkt Outperform	$70
Jul-08-24	Initiated	BTIG Research	Buy	$90
Jun-27-24	Initiated	Stifel	Buy	$86
May-06-24	Initiated	H.C. Wainwright	Buy	$65
Apr-03-24	Initiated	Evercore ISI	Outperform	$65
Mar-28-24	Initiated	RBC Capital Mkts	Outperform	$70
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight	$7
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight	$10

Show Previous Ratings

Oct-15-26 08:00AM	Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy (GlobeNewswire) +6.21%
Oct-07-26 08:00AM	Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants (GlobeNewswire)
Sep-15-26 04:05PM	Jasper Therapeutics Announces Key Regulatory and Clinical Appointments (GlobeNewswire) -9.91%
Sep-09-26 08:00AM	Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-17-26 08:30AM	Jasper Therapeutics beats Q2 expectations but shares fall after results (InvestorsHub) +6.59%
11:00AM	Loading…
Aug-14-26 11:00AM	Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -8.46%
Jul-17-26 07:54AM	Jasper gets a lifeline in merger with immune drugmaker Kira (BioPharma Dive) +14.34%
Jul-16-26 05:15PM	Jasper Therapeutics Announces Merger with Kira Pharmaceuticals (GlobeNewswire) +11.85%
Jun-01-26 08:00AM	Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (GlobeNewswire) -35.56%
May-14-26 04:05PM	Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) -11.36%
Mar-30-26 04:30PM	Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -14.29%
Feb-24-26 04:30PM	Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Jan-09-26 07:15AM	Jasper Therapeutics reports updated data from briquilimab studies (TipRanks) -9.04%
Jan-08-26 07:00AM	Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria (GlobeNewswire) -19.02%
Jan-07-26 04:30PM	Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth (GlobeNewswire) +7.89%
07:00AM	Loading…
Dec-02-25 07:00AM	Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation (GlobeNewswire) -8.14%
Dec-01-25 04:30PM	Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation (GlobeNewswire) -6.52%
Nov-11-25 02:15AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Nov-10-25 08:00AM	Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-25 03:37AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Nov-04-25 08:00AM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -13.81%
Oct-20-25 03:21AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Oct-07-25 08:04AM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire)
Sep-25-25 04:46PM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR (PR Newswire) +6.01%
Sep-22-25 05:58PM	Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights JSPR (Business Wire) -5.51%
Sep-19-25 12:07AM	Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants (GlobeNewswire)
Sep-18-25 04:08PM	Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants (GlobeNewswire) +11.16%
Aug-27-25 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 04:05PM	Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-25 08:00AM	Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway (GlobeNewswire) +21.85%
07:30AM	Loading…
Jul-07-25 07:30AM	Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria (GlobeNewswire) -55.10%
Jun-14-25 10:00AM	Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire)
Jun-03-25 08:00AM	Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress (GlobeNewswire) +8.26%
May-21-25 11:23AM	Jasper Therapeutics, Inc. (JSPR): Analysts See 914% Upside Potential (Insider Monkey)
May-14-25 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-12-25 04:05PM	Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-19-25 04:21PM	Jasper Therapeutics files $300M mixed securities shelf (SeekingAlpha)
Mar-01-25 12:45PM	Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-28-25 08:00AM	Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Feb-27-25 08:00AM	Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 04:30PM	Jasper Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 08:00AM	Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-04-25 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) +8.23%
Jan-08-25 07:00AM	Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire) -60.53%
Jan-06-25 08:00AM	Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025 (GlobeNewswire) +8.30%
Dec-02-24 04:30PM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma (GlobeNewswire) +5.09%
Nov-13-24 04:30PM	Jasper Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-08-24 11:28AM	Analysts Bullish on Jasper Therapeutics as Briquilimab Trials Show Promise (GuruFocus.com) +8.11%
Nov-07-24 07:30AM	Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-24 08:00AM	Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-23-24 08:00AM	Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria (GlobeNewswire)
Oct-14-24 07:00AM	Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +10.46%
Sep-10-24 07:30AM	Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma (GlobeNewswire) +5.13%
Sep-04-24 04:30PM	Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 07:00AM	Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.40%
Jun-19-24 08:00AM	Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors (GlobeNewswire)
Jun-17-24 04:30PM	Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit (GlobeNewswire)
Jun-14-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress (GlobeNewswire)
May-30-24 06:05PM	Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024 (GlobeNewswire) +7.72%
May-29-24 04:30PM	Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-13-24 08:00AM	Jasper Therapeutics Announces Briquilimab Development Program in Asthma (GlobeNewswire)
May-07-24 04:30PM	Jasper Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire) -6.94%
12:00PM	Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-02-24 04:30PM	Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-22-24 08:50AM	Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-21-24 04:30PM	Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) +8.01%
Mar-19-24 08:00AM	Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria (GlobeNewswire) +5.55%
Mar-15-24 08:00AM	New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia (GlobeNewswire)
Mar-14-24 12:00PM	Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know (Zacks) -9.11%
Mar-06-24 12:53PM	JSPR Stock Earnings: Jasper Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +8.21%
08:50AM	Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going (Zacks)
Mar-04-24 07:30AM	Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Feb-26-24 04:30PM	Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-23-24 08:00AM	Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire)
Feb-19-24 08:50AM	Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength (Zacks)
Feb-07-24 08:00AM	Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire) +18.00%
Feb-06-24 08:59AM	Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock (GlobeNewswire) +14.52%
Feb-05-24 08:00AM	Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting (GlobeNewswire) +7.65%
Feb-02-24 08:00AM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-24 12:14PM	Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why (Zacks)
Jan-05-24 08:30AM	Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones (GlobeNewswire)
Jan-02-24 08:00AM	Jasper Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -13.74%
Dec-18-23 04:30PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.11%
Dec-10-23 11:00AM	Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 (GlobeNewswire)
Nov-30-23 08:00AM	Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Nov-09-23 09:48AM	Jasper Therapeutics Inc (JSPR) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) -8.08%
08:00AM	Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-08-23 04:30PM	Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences (GlobeNewswire)
Nov-02-23 09:00AM	Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors (GlobeNewswire)
Oct-09-23 08:30AM	Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023 (GlobeNewswire) +16.25%
08:00AM	Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria (GlobeNewswire)
Sep-25-23 08:00AM	Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer (GlobeNewswire) -8.97%
Sep-21-23 08:00AM	Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium (GlobeNewswire)
Sep-15-23 08:00AM	Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference (GlobeNewswire) +10.96%
Aug-11-23 04:05PM	Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-23 04:51PM	Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-02-23 08:00AM	Jasper Therapeutics Strengthens Management Team with Key Appointments (GlobeNewswire)

Show Previous News

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

MBAJeet Mahal

SCTX

Scribe Therapeutics Inc

JSPR

Jasper Therapeutics Inc

Upgrade your Finviz experience